Gastroenterology

Results from RESPONSE show seladelpar may improve measures of disease activity and reduce symptom burden in patients with PBC.

Patients with CDI treated with oral metronidazole experienced significantly more first-line drug changes compared to those on fidaxomicin, although there were no significant differences observed in the global or clinical cure rate between the two treatments.

Investigators observed higher rates of clinical and endoscopic remission among patients with UC treated with FMT compared to those on control treatments, further noting comparable rates of adverse reactions between the groups.

Vedolizumab, anti-TNF, and 5-ASA treatments were not linked to an increased risk of CDI, but investigators noted other baseline variables were significantly associated with CDI risk in patients with IBD.

The clinical trial compared outcomes in patients with NAFLD on a resistant starch diet to a control group over a 4-month period, with results suggesting microbiota dietary supplements may improve liver conditions.

Results from the retrospective cohort study indicated viral eradication with DAAs after liver transplantation improved liver function and patient survival after a long-term follow-up, even in cirrhotic patients.

Results from the study found a high risk of CDI associated with clindamycin and low risk associated with doxycycline and minocycline, also highlighting variation in CDI risk within and between classes of antibiotics.

Carolina Mangas-Sanjuan, MD, PhD, discusses findings from her research on the use of artificial intelligence computer-aided detection in colonoscopies in this Q&A with HCPLive.

A population-based cohort study highlighted an association between AD and IBD with risk varying by age, AD severity, and subtype of IBD.

Findings from cross-sectional and predictive analyses of patients with UC treated with upadacitinib revealed HEMR and HEMI are associated with positive long-term clinical outcomes.

Results from two recent studies highlight the potential benefits and limitations of using artificial intelligence technologies in colonoscopies.

Findings from a recent study of patients with IBD on biologic therapy suggest selenium and zinc deficiencies may predict disease outcomes and adverse clinical effects.

AbbVie submitted regulatory applications to the FDA and EMA for rizankizumab 1200 mg intravenous induction dose and 180 mg and 360 mg subcutaneous maintenance dose following successful Phase 3 trials INSPIRE and COMMAND.

Patients receiving systemic corticosteroids faced an increased risk of severe COVID-19 requiring hospitalization or mechanical ventilation compared to other medication classes used to treat IBD.

Hypertension prevalence was significantly higher among adults with obesity and severe NAFLD, providing important information related to the association between hypertension and NAFLD severity.

When evaluating patient-education strategies among individuals with IBD, investigators found vaccine uptake was unaffected by educational videos and text-based interventions, identifying prior vaccine receipt as the strongest predictor of future vaccination.

Diagnostic survey results indicated 62.7% of participating patients with hepatitis C expressed a low level of satisfaction with life.

Data support the benefit of bariatric surgery in patients at high risk of pancreatic ductal adenocarcinoma due to BMI and metabolic comorbidities.

Instances of urgent IBD hospitalization, surgery, death or lack of response to steroid therapy are linked to symptoms of depression and anxiety.

Qazi reviews an analysis of an EHR-assisted smoking cessation module that could improve conversations between specialists and patients.

While discussing a review of noninvasive options, the gastroenterologist addresses the growing interest in non-colonoscopy screening and surveillance methods.

Approximately 1 in 5 newly diagnosed patients are initiating direct acting antivirals within 6 months, according to Medicaid data review.

A Mayo Clinic study shows FMT may provide benefit for patients experiencing recurrent infections during their C difficile treatment.

Qazi reviews the selective JAK1 inhibitor's benefit for patients who previously failed TNF inhibitor regimen.

A multinational study shows people who achieve sustained virologic response still face a 3-fold greater risk or more of mortality due to liver disease or drug-related issues.